Curiously, trabectedin treatment seems to upregulate E2F1 in multiple myeloma [38], which supports the hypothesis that the HMGA1/E2F1 axis could be activated as a mechanism of resistance after trabectedin. Here, HMGA1 is linked to plasma cell myeloma.